S0521
|
SWOG
|
A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL); Phase III
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0600
|
SWOG
|
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX; OPTIMOX or XELOX
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0777
|
SWOG
|
A Randomized Phase III Trial of CC-5013 (Lenalidomide; NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341; NSC-681239); Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction; in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S0819
|
SWOG
|
A Randomized; Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0931
|
SWOG
|
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy; A Phase III Study
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1007
|
SWOG
|
A Phase III; Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes; Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node; Endocrine Responsive Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1011
|
SWOG
|
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1203
|
SWOG
|
A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S1207
|
SWOG
|
Phase III Randomized; Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study - evaluating everolimus with endocrine therapy
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1216
|
SWOG
|
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|